CN113286585A - 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 - Google Patents

血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 Download PDF

Info

Publication number
CN113286585A
CN113286585A CN202080008624.1A CN202080008624A CN113286585A CN 113286585 A CN113286585 A CN 113286585A CN 202080008624 A CN202080008624 A CN 202080008624A CN 113286585 A CN113286585 A CN 113286585A
Authority
CN
China
Prior art keywords
ahu377
exp3174
complex
heart failure
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080008624.1A
Other languages
English (en)
Other versions
CN113286585B (zh
Inventor
孙晶超
景小龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Priority to CN202211186846.XA priority Critical patent/CN115487175B/zh
Publication of CN113286585A publication Critical patent/CN113286585A/zh
Application granted granted Critical
Publication of CN113286585B publication Critical patent/CN113286585B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物治疗心衰的用途，具体涉及所述复合物在制备用于射血分数降低的心衰(HFrEF)的药物用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080008624.1A 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 Active CN113286585B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211186846.XA CN115487175B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910890853 2019-09-20
CN201910890853X 2019-09-20
CN2020109019846 2020-09-01
CN202010901984 2020-09-01
PCT/CN2020/116023 WO2021052441A1 (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211186846.XA Division CN115487175B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Publications (2)

Publication Number Publication Date
CN113286585A true CN113286585A (zh) 2021-08-20
CN113286585B CN113286585B (zh) 2022-11-08

Family

ID=74883393

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211186846.XA Active CN115487175B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
CN202080008624.1A Active CN113286585B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211186846.XA Active CN115487175B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Country Status (13)

Country Link
US (1) US20220395491A1 (zh)
EP (1) EP4032532A4 (zh)
JP (1) JP7316449B2 (zh)
KR (1) KR20220012317A (zh)
CN (2) CN115487175B (zh)
AU (1) AU2020348813A1 (zh)
CA (1) CA3151788A1 (zh)
CO (1) CO2022004910A2 (zh)
EC (1) ECSP22031078A (zh)
MX (1) MX2022003408A (zh)
TW (1) TWI809313B (zh)
WO (1) WO2021052441A1 (zh)
ZA (1) ZA202204370B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443272A (zh) * 2020-08-17 2022-12-06 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用
CN115487175A (zh) * 2019-09-20 2022-12-20 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
AU2004203284A1 (en) * 1998-11-06 2004-08-12 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
WO2015028941A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use
WO2016181284A1 (en) * 2015-05-11 2016-11-17 Novartis Ag Sacubitril-valsartan dosage regimen for treating heart failure
CN106924241A (zh) * 2017-04-28 2017-07-07 广州医科大学 川陈皮素在预防或治疗心衰药物中的应用
CN108473474A (zh) * 2016-01-20 2018-08-31 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
TW201336839A (zh) * 2012-02-15 2013-09-16 Theravance Inc （２ｓ，４ｒ）－５－聯苯－４－基－２－羥甲基－２－甲基－４－［（１ｈ－［１，２，３］三唑－４－羰基）－胺基］－戊酸５－甲基－２－酮基－［１，３］二氧雜環戊烯－４－基甲酯之結晶型
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
WO2017006254A1 (en) * 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
US10100021B2 (en) * 2016-03-08 2018-10-16 Theravance Biopharma R&D Ip, Llc Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
CN106177960B (zh) * 2016-08-01 2019-01-08 珠海赛隆药业股份有限公司（长沙）医药研发中心 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途
WO2020236736A1 (en) * 2019-05-19 2020-11-26 MyoKardia, Inc. Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
US20220226285A1 (en) * 2019-05-30 2022-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment Method Using A Complex of Angiotensin II Receptor Antagonist Metabolite and NEP Inhibitor
EP4032532A4 (en) * 2019-09-20 2023-10-04 Shenzhen Salubris Pharmaceuticals Co. Ltd USES OF A COMPLEX CONSISTING OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLISM AND A NEP INHIBITOR IN THE TREATMENT OF HEART FAILURE
WO2022037512A1 (zh) * 2020-08-17 2022-02-24 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004203284A1 (en) * 1998-11-06 2004-08-12 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
WO2015028941A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use
WO2016181284A1 (en) * 2015-05-11 2016-11-17 Novartis Ag Sacubitril-valsartan dosage regimen for treating heart failure
CN108473474A (zh) * 2016-01-20 2018-08-31 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
CN106924241A (zh) * 2017-04-28 2017-07-07 广州医科大学 川陈皮素在预防或治疗心衰药物中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ZHANG JIANQI 等: "Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hyperten¬sion", 《 MEDICINE 》 *
杨昌生: "射血分数保留的心力衰竭的治疗", 《中华临床医师杂志(电子版)》 *
杨瑞峰: "β受体阻滞剂治疗慢性心力衰竭的临床观察", 《中国现代医生》 *
谭漪扬等: "慢性心力衰竭治疗新进展――LCZ696!", 《心血管病学进展》 *
马岚等: "血管紧张素受体-脑啡肽酶抑制剂在心力衰竭中的应用", 《 世界临床药物》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115487175A (zh) * 2019-09-20 2022-12-20 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
CN115487175B (zh) * 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
CN115443272A (zh) * 2020-08-17 2022-12-06 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用
CN115443272B (zh) * 2020-08-17 2023-11-17 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用

Also Published As

Publication number Publication date
CO2022004910A2 (es) 2022-05-31
ECSP22031078A (es) 2022-08-31
CA3151788A1 (en) 2021-03-25
TW202114652A (zh) 2021-04-16
CN113286585B (zh) 2022-11-08
US20220395491A1 (en) 2022-12-15
WO2021052441A1 (zh) 2021-03-25
TWI809313B (zh) 2023-07-21
MX2022003408A (es) 2022-07-12
JP7316449B2 (ja) 2023-07-27
EP4032532A1 (en) 2022-07-27
AU2020348813A1 (en) 2022-04-14
JP2022545904A (ja) 2022-11-01
KR20220012317A (ko) 2022-02-03
EP4032532A4 (en) 2023-10-04
ZA202204370B (en) 2022-11-30
CN115487175B (zh) 2024-05-14
CN115487175A (zh) 2022-12-20

Similar Documents

Publication Publication Date Title
CN115443272B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用
RU2720204C1 (ru) Сублингвальная фармацевтическая композиция эдаравона и (+)-2-борнеола
TWI657826B (zh) Complex of angiotensin II receptor antagonist metabolite and NEP inhibitor and preparation method thereof
CN113286585B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
CN107344927A (zh) Tafamidis葡甲胺盐的晶型E及其制备方法和用途
JP2024039020A (ja) サルカルディン塩
CN115461052B (zh) Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
WO2022233310A1 (zh) 丹酚酸a盐水合物、其制备方法及用途
CN105147703B (zh) 黄柏酮在制备防治溃疡性结肠炎的药物中的应用
CN102558224A (zh) 甲磷丙泊酚钠水合物及其制备方法和用途
CN108904501B (zh) 一种化合物在治疗或预防高原病中的用途
US4218466A (en) Method of treating gastric and duodenal ulcers
CN104983728B (zh) 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用
US20120225817A1 (en) Therapeutic agent for gastrointestinal disease
McArthur et al. A comparative study of indomethacin and ibuprofen
BR112020010115A2 (pt) formulação em folha para uso oral
Bailie et al. Traumatic perforation of the lower oesophagus
CN114075260A (zh) 化合物p57或其类似物用于体温降低和神经保护的用途
JP2007528878A (ja) 新規２−（α−ｎ−ペンタノニル）安息香酸塩及びその製造方法と用途
JPH06192080A (ja) 脳浮腫の予防および治療剤
JPS60346B2 (ja) Ｓ−（３−メチル−２−ブテニル）システインならびにその製法
Ophth of Current Literature
CN106265638A (zh) Linderolide H在制备治疗或预防口腔溃疡药物中的应用
CN107281209A (zh) 一种抗胃溃疡的药物组合物及其制备方法与用途
CN105601491A (zh) 一种治疗心肌炎的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052758

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Applicant before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

GR01 Patent grant
GR01 Patent grant